HAYWARD, Calif., Feb. 10, 2000 (PRIMEZONE) -- Questcor Pharmaceuticals, Inc. (AMEX:QSC) shares have been recommended in an updated analyst report released by WallStreet Research, a prominent research boutique led by Alan Stone, managing director of Alan Stone & Company, LLC.
Stone was formerly an analyst and assistant portfolio manager at Merrill Lynch Asset Management and securities analyst at Prudential Insurance Company's Capital Markets Group.
WallStreet Research specializes in the microcap and smallcap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities.
The report on Questcor Pharmaceuticals, Inc. is available, together with additional information about WallStreet Research, at www.WallSt-Research.com.
Questcor Pharmaceuticals, Inc. is a specialty pharmaceutical company serving the needs of the acute care and critical care hospital market. The company has an extensive pipeline of pharmaceuticals, including four currently marketed acute care products, two late clinical Phase III critical care drugs, and several clinical Phase II and earlier research developments.
Trading on the AMEX under the symbol QSC since its formation through a merger between RiboGene, Inc. and Cypros Pharmaceutical Corporation in November 1999, Questcor has emerged as a well-balanced, fully-integrated pharmaceutical company within the small-cap arena.
Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors which may cause the companies' results to differ. Factors that may cause such differences include, but are not limited to, the company's need for additional funding, uncertainties regarding the company's intellectual property and other research, development, marketing and regulatory risks as well as the risks discussed in Cypros' Annual Report on Form 10-K for the fiscal year ended July 31, 1999 and the Risk Factor section of Cypros' Registration Statement (No. 333-25661), RiboGene's Annual Report on Form 10-K for the fiscal year ended Dec. 31, 1998 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.